Abstract

Stability of Captopril in SyrSPend SF

Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul A

Issue: Jul/Aug 2013 - Volume 17, Number 4

Page(s): 336-338

Download in electronic PDF format for $75
  • Stability of Captopril in SyrSPend SF Page 1
  • Stability of Captopril in SyrSPend SF Page 2
  • Stability of Captopril in SyrSPend SF Page 3

Abstract

Captopril is an angiotensin-converting enzyme inhibitor available as a tablet. Patients who are unable to take tablets have led compounding pharmacies to seek alternative dosage forms including solutions and suspensions. The objective of this study was to determine the stability of captopril in sorbitol-free, alcohol-free SyrSpend SF suspending agent. The studied samples were compounded into a 0.8-mg/mL suspension and stored in low-actinic plastic bottles at temperatures between 2°C to 8°C. Six samples were assayed at each time point out to 32 days by a stability- indicating high-performance liquid chromatography method. The samples remained within 90% to 110% of the initial concentration throughout day 14 of the study. Based on the data collected, the beyond-use date of these preparations is 14 days when protected from light and refrigerated.

Related Keywords

  • captopril
  • angiotensin-converting enzyme inhibitor
  • ACE inhibitor
  • oral suspension
  • stability-indicating high-performance liquid chromatography
  • HPLC
  • forced degradation studies
  • storage conditions

Related Categories

  • EXCIPIENTS
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • CARDIOLOGY
  • STORAGE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2013
Pg. 336-338
Stability of Captopril in SyrSPend SF
Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul A
Mar/Apr 2019
Pg. 148
Captopril 0.8 mg/mL in SyrSpend SF Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2013
Pg. 344-346
Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry
Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul A
May/Jun 2004
Pg. 223-227
Quality-Control Analytical Methods: High-Performance Liquid Chromatography
Author(s): Kupiec Thomas C
May/Jun 2003
Pg. 170-174
Five Compounds for Treating Diabetes-Related Conditions
Author(s): Meece Jerry
Mar/Apr 2016
Pg. 167-174
Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Author(s): Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MA
Mar/Apr 2017
Pg. 164-170
Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs
Author(s): Gorman Gregory, Sokom Simara, Coward Lori, Arnold John J
Nov/Dec 2018
Pg. 494
Enalapril Maleate 1 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 1999
Pg. 314-315
Quantitation of Testosterone-Cypionate-in-Oil Injection using High Performance Liquid Chromatography
Author(s): Gupta Vishnu D, Pramar Y
Mar/Apr 1999
Pg. 158-159
Quantitation of Testosterone Propionate in an Injection Using High Performance Liquid Chromatography
Author(s): Gupta Vishnu D
Jul/Aug 2017
Pg. 322-329
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Author(s): Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
Jul/Aug 2017
Pg. 339-346
Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4
Author(s): de Oliveira Ferreira Anderson, Polonini Hudson, Loures da Silva Sharlene, Buzinari Aglio Natália Cristina, Abreu Jordana, Fernandes Brandão Marcos Antônio
Sep/Oct 2014
Pg. 427-431
Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition
Author(s): Bourget Philippe, Amin Alexandre, Vidal Fabrice, Pieyre Manon, Dosso El Ourmar, Beauvais Raphaelle, Loeuillet Richard
Nov/Dec 2014
Pg. 456-460
Standards of Practice, Professional Judgment, and Scientific Evidence to Establish and Extend a Beyond-Use Date
Author(s): Thomson Cassandra Marie, Savji Taslim
Mar/Apr 2011
Pg. 124-128
Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease
Author(s): Corsini Lindsay, Williams LaVonn A
Sep/Oct 2003
Pg. 389-393
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Author(s): Alexander Kenneth S, Thyangarajapuram N
Sep/Oct 2015
Pg. 420-427
Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF
Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul
Jul/Aug 2020
Pg. 318
Lisinopril 1 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 327-336
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Jul/Aug 2017
Pg. 334-338
Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt
Author(s): Graves Richard, Phan Kelly V, Bostanian Levon A, Mandal Tarun K, Pramar Yashoda V